P Moreau

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. ncbi request reprint Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra
    Philippe Moreau
    Service d Hematologie, University Hospital Hotel Dieu, Place Alexis Recordeau, 44093 Nantes Cedex 01, France
    Blood 99:731-5. 2002
  2. doi request reprint Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093, Nantes, France
    Drugs 76:853-67. 2016
  3. doi request reprint Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
    Philippe Moreau
    Hematology Department, UMR892, University Hospital, Place Ricordeau, Nantes 44093, France Electronic address
    Hematol Oncol Clin North Am 28:829-38. 2014
  4. pmc RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway
    Sylvanie Surget
    CRCNA, INSERM, UMR 892, Nantes F 44000, France
    BMC Cancer 14:437. 2014
  5. pmc Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related
    Philippe Moreau
    Philippe Moreau, University Hospital Hôtel Dieu Jean Luc Harousseau, Centre Rene Gauducheau, Nantes Michel Attal, Centre Hospitalier Universitaire CHU Toulouse Hervé Avet Loiseau, CHU Rangueil, Toulouse Gerald Marit, University Hospital of Bordeaux, Bordeaux Cyrille Hulin, CHU Nancy, Nancy Thierry Facon, Hopital Claude Huriez Xavier Leleu, University Hospital of Lille, Lille Denis Caillot, CHU Dijon, Dijon Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours Jean Yves Mary, University Hospital Paris Saint Louis, Paris, France Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna Antonio Palumbo, University of Torino, Torino Maria Teresa Petrucci, Sapienza University of Rome, Rome Francesca Patriarca, University Hospital, Udine, Italy Pieter Sonneveld, Erasmus Medical Center, Rotterdam Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Toulouse
    J Clin Oncol 32:2173-80. 2014
  6. doi request reprint Initial treatment of transplant candidates with multiple myeloma
    Philippe Moreau
    Department of Hematology, University Hospital Hotel Dieu, Nantes, France Electronic address
    Semin Oncol 40:585-91. 2013
  7. pmc Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    Bertrand Arnulf
    Immuno Hématologie Department, Hôpital Saint Louis Centre d Investigations Cliniques, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    Haematologica 97:1925-8. 2012
  8. doi request reprint Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma
    Philippe Moreau
    University Hospital, Nantes, France
    Clin Pharmacokinet 51:823-9. 2012
  9. doi request reprint Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Leuk Res 36:S13-8. 2012
  10. pmc Proteasome inhibitors in multiple myeloma: 10 years later
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Blood 120:947-59. 2012

Detail Information

Publications118 found, 100 shown here

  1. ncbi request reprint Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Fra
    Philippe Moreau
    Service d Hematologie, University Hospital Hotel Dieu, Place Alexis Recordeau, 44093 Nantes Cedex 01, France
    Blood 99:731-5. 2002
    ..This regimen should be considered as the standard of care before autologous stem cell transplantation in multiple myeloma...
  2. doi request reprint Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093, Nantes, France
    Drugs 76:853-67. 2016
    ..Our review provides an overview of the results from the daratumumab clinical trials conducted to date, as well as practical management considerations for the use of daratumumab based on our experience with the agent. ..
  3. doi request reprint Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
    Philippe Moreau
    Hematology Department, UMR892, University Hospital, Place Ricordeau, Nantes 44093, France Electronic address
    Hematol Oncol Clin North Am 28:829-38. 2014
    ..This article focuses on more recent therapeutic approaches in older MM patients, not eligible for high-dose therapy and autologous stem cell transplantation. ..
  4. pmc RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway
    Sylvanie Surget
    CRCNA, INSERM, UMR 892, Nantes F 44000, France
    BMC Cancer 14:437. 2014
    ..The aim of this study was to evaluate the efficacy of the p53-reactivating drugs RITA and nutlin3a in killing myeloma cells...
  5. pmc Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related
    Philippe Moreau
    Philippe Moreau, University Hospital Hôtel Dieu Jean Luc Harousseau, Centre Rene Gauducheau, Nantes Michel Attal, Centre Hospitalier Universitaire CHU Toulouse Hervé Avet Loiseau, CHU Rangueil, Toulouse Gerald Marit, University Hospital of Bordeaux, Bordeaux Cyrille Hulin, CHU Nancy, Nancy Thierry Facon, Hopital Claude Huriez Xavier Leleu, University Hospital of Lille, Lille Denis Caillot, CHU Dijon, Dijon Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours Jean Yves Mary, University Hospital Paris Saint Louis, Paris, France Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna Antonio Palumbo, University of Torino, Torino Maria Teresa Petrucci, Sapienza University of Rome, Rome Francesca Patriarca, University Hospital, Udine, Italy Pieter Sonneveld, Erasmus Medical Center, Rotterdam Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Toulouse
    J Clin Oncol 32:2173-80. 2014
    ..To construct and validate among patients with multiple myeloma (MM) who were treated with intensive therapy a prognostic index of early MM progression-related death...
  6. doi request reprint Initial treatment of transplant candidates with multiple myeloma
    Philippe Moreau
    Department of Hematology, University Hospital Hotel Dieu, Nantes, France Electronic address
    Semin Oncol 40:585-91. 2013
    ..This review will focus on the most recent results of novel agent-based induction therapies, as well as on interesting developments in the transplant phase that are aimed at improving the results of conditioning regimens. ..
  7. pmc Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    Bertrand Arnulf
    Immuno Hématologie Department, Hôpital Saint Louis Centre d Investigations Cliniques, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
    Haematologica 97:1925-8. 2012
    ..Peripheral neuropathy rates remained significantly lower with subcutaneous versus intravenous bortezomib, with increased rates of improvement/resolution at the time of this analysis...
  8. doi request reprint Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma
    Philippe Moreau
    University Hospital, Nantes, France
    Clin Pharmacokinet 51:823-9. 2012
    ....
  9. doi request reprint Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Leuk Res 36:S13-8. 2012
    ....
  10. pmc Proteasome inhibitors in multiple myeloma: 10 years later
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Blood 120:947-59. 2012
    ..This review provides an overview of the role of PIs in the treatment of MM, focusing on developments over the past decade...
  11. doi request reprint The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies
    Philippe Moreau
    University Hospital Hotel Dieu, Nantes, France
    Semin Hematol 49:S33-46. 2012
    ..This article describes emerging antimyeloma agents in mid-stage to late-stage clinical development, and highlights the novel treatment approaches and combination strategies being evaluated in the relapsed/refractory setting...
  12. ncbi request reprint A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
    P Moreau
    Haematology Department, CHU Hotel Dieu, Nantes, and Diaclone Research, Besancon, France
    Br J Haematol 109:661-4. 2000
    ..A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy...
  13. ncbi request reprint Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:397-403. 2006
    ..39). In high-risk patients the dose intensity of melphalan at 420 mg/m2 led to encouraging results, but the addition of anti-IL-6 monoclonal antibody to the second conditioning regimen did not improve either OS nor EFS...
  14. ncbi request reprint [Multiple bone myelomas]
    Philippe Moreau
    Hématologie Clinique, Centre Hospitalier Universitaire, 44093 Nantes
    Rev Prat 56:763-8. 2006
  15. ncbi request reprint [New drugs for myeloma]
    Philippe Moreau
    Service d Hematologie Clinique, CHU Hotel Dieu, Nantes
    Presse Med 35:1303-8. 2006
    ..These different drugs can be used successively at relapse, making myeloma a chronic disease. They can also be used together for greater effectiveness. These combinations will replace conventional chemotherapies in the future...
  16. doi request reprint Frontline treatment of multiple myeloma in elderly patients
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place A Ricordeau, 44093 Nantes Cedex, France
    Blood Rev 22:303-9. 2008
    ..Thus, at least four highly active new treatment options are now available to treat elderly patients with MM. The goal of future trials will be to determine the best treatment strategy in this group of patients...
  17. doi request reprint Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
    Philippe Moreau
    Department of Hematology, University Hospital, Nantes, France
    Haematologica 93:1908-11. 2008
    ..Based on these exploratory findings, subcutaneous administration offers an alternative option to intravenous injection (ClinicalTrials.gov identifier: NCT00291538)...
  18. doi request reprint Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma
    Philippe Moreau
    Hematology Department, CHU Hotel Dieu, 44093 Nantes, France
    Expert Rev Anticancer Ther 9:885-90. 2009
    ..The aim of this article is to summarize the more recent data available on the efficacy of these combinations and to discuss their role as part of initial therapy...
  19. doi request reprint Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
    Philippe Moreau
    University Hospital, Nantes, France
    Blood 116:4777-82. 2010
    ..019). Lenalidomide 15 mg/d + M-dex is a new effective combination therapy in patients with newly diagnosed AL amyloidosis. This study is registered at www.clinicaltrials.gov as NCT00621400...
  20. doi request reprint Communications on multiple myeloma
    Philippe Moreau
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093 Nantes, France
    Expert Rev Hematol 2:129-31. 2009
    ..Interesting new data on the latest drugs, treatment of patients younger or older than 65 years, and new combinations were discussed...
  21. doi request reprint New developments in conditioning regimens before auto-SCT in multiple myeloma
    P Moreau
    Hematology Department, University Hospital Hotel Dieu, Nantes, France
    Bone Marrow Transplant 46:911-5. 2011
    ..Several attempts have recently been made to improve this aspect of the high-dose therapy procedure. The scope of this review article is to summarize current knowledge on conditioning regimens in this setting...
  22. doi request reprint Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Philippe Moreau
    University Hospital, Nantes, France
    Lancet Oncol 12:431-40. 2011
    ..We compared the efficacy and safety of subcutaneous versus intravenous bortezomib at the approved 1·3 mg/m(2) dose and twice per week schedule in patients with relapsed multiple myeloma...
  23. pmc Minor clone provides a reservoir for relapse in multiple myeloma
    F Magrangeas
    INSERM UMR 892, CNRS UMR 6299, Universite de Nantes, Nantes, France
    Leukemia 27:473-81. 2013
    ..These data support the idea that new strategies for future clinical trials in MM should combine targeted therapy and subpopulations' control to eradicate all myeloma subclones in order to obtain long-term remission...
  24. ncbi request reprint Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma
    P Moreau
    Department of Hematology, University Hospital, Nantes, France
    Leukemia 16:1838-43. 2002
    ..This survival is significantly influenced by age (< or =55 years), B2M at diagnosis (< or =3 mg/l) and by the completion of two cycles of HDT...
  25. doi request reprint Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation
    Z Peric
    Service d Hematologie Clinique, Centre Hospitalier et Universitaire CHU de Nantes, Nantes, France
    Bone Marrow Transplant 47:251-7. 2012
    ..We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD...
  26. ncbi request reprint Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome
    M Michallet
    , Paris, France
    J Clin Oncol 19:3340-9. 2001
    ..CONCLUSION: This series shows encouraging results from nonmyeloablative conditioning regimens before allotransplantation and demonstrates the impact of some pre- and posttransplantation factors on outcome after transplantation...
  27. doi request reprint Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning
    F Malard
    1 Centre Hospitalier et Universitaire CHU de Nantes, Service d Hematologie Clinique, Nantes, France 2 INSERM CRNCA UMR 892, Universite de Nantes, Faculte de Medecine, Nantes, France
    Leukemia 27:2113-7. 2013
    ..3% (95% CI, 23.2-53.3%) in the MisMUD group (P=0.55). These data suggest that dUCB is a valid alternative graft source with significantly less chronic GVHD compared with MisMUD in the setting of RIC allo-SCT...
  28. pmc Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
    S Maiga
    INSERM, UMR892, Departement de Recherche en Cancerologie Nantes Angers, 8, quai Moncousu, Nantes 44007, France
    Br J Cancer 108:1801-6. 2013
    ..However, the molecular mechanisms driving these activities are not yet fully elucidated. Therefore, we investigated the modulation of the cytokine/growth factor patterns of myeloma cells under LEN treatment...
  29. doi request reprint Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
    V Roland
    Centre Hospitalier Universitaire de Nantes, Service d Hematologie Clinique, Nantes, France
    Bone Marrow Transplant 46:393-9. 2011
    ..These results suggest that HDC-ASCT can significantly improve the bad prognosis, otherwise indicated by a positive interim FDG-PET...
  30. ncbi request reprint Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    P Moreau
    Hematology Department, University Hospital, Nantes, France
    Leukemia 21:2020-4. 2007
    ..The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS...
  31. doi request reprint Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
    T Guillaume
    Centre Hospitalier et Universitaire CHU de Nantes, Hématologie Clinique, 1 place Ricordeau, Nantes, France
    Bone Marrow Transplant 47:1112-7. 2012
    ..However, a peripheral expansion of DCs was observed. These findings suggest that the escalated dose procedure appears safe and prevent overwhelming toxicity. A dose-limiting toxicity has not yet been reached...
  32. doi request reprint Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation
    Z Peric
    Centre Hospitalier et Universitaire CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Leukemia 25:932-8. 2011
    ..However, this did not impact on outcome, as quantitative monitoring of EBV viral load by PCR and preemptive rituximab therapy allowed for significantly reducing the risk of EBV-related LPD...
  33. ncbi request reprint Use of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma
    H Avet-Loiseau
    University Hospital, Nantes, France Dana Farber Cancer Institute, Boston, MA Harvard Medical School, Boston, MA Dana Farber Cancer Institute, Boston, MA Gauducheau Cancer Center, Saint Herblain, France
    J Clin Oncol 26:8522. 2008
    ..Even though cytogenetics is a difficult art in myeloma, chromosomal abnormalities are present in 100% of the patients, and some preliminary data have shown that some chromosomal abnormalities are highly predictive of a short survival...
  34. doi request reprint Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G
    L Gineau
    1 Institute of Research for Development, Mixed Research Unit 216 MERIT, Paris, France 2 Faculté de Pharmacie, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Genes Immun 16:57-70. 2015
    ..An extended analysis of a 300-kb region surrounding HLA-G revealed that this region is not involved in a hitchhiking effect and may be the direct target of selection. ..
  35. ncbi request reprint Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy
    M A Mahe
    Centre Rene Gauducheau, Cedex, France
    Int J Radiat Oncol Biol Phys 47:735-8. 2000
    ..To evaluate the efficacy of total abdominopelvic (TAI) and total body irradiation (TBI) in heavily pretreated follicular non-Hodgkin's lymphoma (NHL)...
  36. ncbi request reprint Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants
    E Ninin
    Laboratoire de Bacteriologie Virologie Hygiene Hospitaliere, Institut de Biologie des Hopitaux de Nantes, Nantes, France
    Clin Infect Dis 33:41-7. 2001
    ....
  37. doi request reprint Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
    H Avet-Loiseau
    Institut National de la Sante et de la Recherche Medicale INSERM, Unite 892, Nantes, France
    Leukemia 24:623-8. 2010
    ....
  38. doi request reprint Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials
    Jean Luc Harousseau
    Centre René Gauducheau Bd Jacques Monod 44850 St Herblain, Nantes, France
    J Clin Oncol 27:5720-6. 2009
    ..The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy...
  39. doi request reprint Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study
    A Lassalle
    Department of Hematology, University Hospital Hotel Dieu, Nantes, France
    Ann Oncol 27:314-8. 2016
    ..No study has as yet prospectively evaluated home versus hospital administration of s.c. bortezomib with respect to patient preference and cost...
  40. doi request reprint Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution
    E Brissot
    Service d Hematologie Clinique, CHU de Nantes, Nantes, France
    Bone Marrow Transplant 51:267-72. 2016
    ..However, post-transplant relapse remains the leading cause of failure of this therapeutic approach, and preventing relapse represents a major challenge today...
  41. doi request reprint Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
    J Bourcier
    Department of Hematology, University Hospital of Nantes, Nantes, France
    Ann Hematol 95:1287-93. 2016
    ..78 % without (p = 0.059). The present monocentric study shows that 2 years of RM after ASCT significantly increases response duration for non-naive rituximab relapsed FL patients compared with observation. ..
  42. doi request reprint Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT
    B Tessoulin
    1 Centre Hospitalier et Universitaire CHU de Nantes, Hématologie Clinique, Nantes, France 2 INSERM CRCNA, UMR 892, Nantes, France
    Bone Marrow Transplant 49:567-71. 2014
    ..Early administration of azacitidine after transplant followed by DLI should be considered as a pre-emptive therapy for potential relapse in patients with minimal residual disease or high-risk myeloid malignancies...
  43. doi request reprint 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study
    C Bodet-Milin
    1 Centre Hospitalier et Universitaire CHU de Nantes, Service de Médecine Nucléaire Nantes, Nantes, France 2 Université de Nantes, Faculte de Medecine, Nantes, France 3 INSERM CRNCA UMR 892, Nantes, France
    Bone Marrow Transplant 49:131-7. 2014
    ....
  44. pmc A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
    G Descamps
    Centre de Recherches en Cancérologie Nantes Angers, INSERM, UMR 892, UFR Médecine et Techniques Médicales, Universite de Nantes, Nantes Atlantique Universites, Nantes, France
    Br J Cancer 100:366-9. 2009
    ..These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14)...
  45. ncbi request reprint Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial
    J L Harousseau
    Hoteldieu Hospital, Nantes, France Intergroupe Francophone du Myelome, Paris, France Millennium Pharmaceuticals, Cambridge, MA
    J Clin Oncol 26:8505. 2008
    ..Improving CR rate has been associated with prolonged PFS and OS. Phase 2 studies have shown bortezomib (VELCADE)/dexamethasone (Vel/Dex) as an effective induction therapy...
  46. doi request reprint Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule
    C Menier
    Commissariat à l Energie Atomique DSV IBM, Service de Recherches en Hemato Immunologie, Paris, France
    Tissue Antigens 75:201-6. 2010
    ..Furthermore, the role of HLA-G during pregnancy was revisited and its impact in pathologies such as cancer, autoimmune disorders and transplantation was further extended...
  47. doi request reprint Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
    B Hébraud
    Unité de Génomique du Myélome, University Hospital, CRCT, INSERM U 1037, Universite Paul Sabatier, Toulouse, France
    Leukemia 28:675-9. 2014
    ..In conclusion, our data show that 1p22 and 1p32 deletions are major negative prognostic factors for PFS and OS for patients with MM. We thus suggest that 1p32 deletion should be tested for all patients at diagnosis. ..
  48. doi request reprint Increased Th17/Treg ratio in chronic liver GVHD
    F Malard
    1 CRNCA, UMR 892 INSERM 6299 CNRS, Nantes, France 2 Service d Hématologie Clinique, Centre Hospitalier et Universitaire CHU, Universite de Nantes, Nantes, France
    Bone Marrow Transplant 49:539-44. 2014
    ....
  49. ncbi request reprint Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy
    S Vigouroux
    University Hospital, Nantes, France
    Bone Marrow Transplant 29:833-42. 2002
    ..02; and 92% vs 77% for OS, P = 0.2; and for the groups with a response <50%: 80% vs 22% for FFP, P = 0.0003; 72% vs 13% for EFS, P = 0.0001; and 76% vs 46% for OS, P = 0.04. This study shows a better control of the disease with HDT...
  50. doi request reprint Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
    G Damaj
    University Hospital, Hematology, Amiens, France
    Leuk Lymphoma 53:632-4. 2012
    ....
  51. ncbi request reprint Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients
    B M Imbert-Marcille
    Laboratoire de Virologie, Institut de Biologie des Hopitaux de Nantes, Nantes, France
    Clin Infect Dis 31:881-6. 2000
    ..000001). Infusion of bone marrow as the source of graft, reactivation occurring before platelet or neutrophil engraftment, and presence of HHV-6 DNA in plasma were identified as risk factors for symptomatic HHV-6 infection (P<.002)...
  52. ncbi request reprint Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
    Jean Luc Harousseau
    Hopital Hotel Dieu, Place Alexis Ricordeau, Nantes Cedex 44093, France
    Haematologica 91:1498-505. 2006
    ..The use of novel agents may increase the CR rate before ASCT, which may improve post-transplantation response and survival...
  53. ncbi request reprint The X1 box of HLA-G promoter is a target site for RFX and Sp1 factors
    P Rousseau
    CEA, Service de Recherche en Hémato Immunologie, DSV DRM, Hopital Saint Louis, Institut d Hematologie, Paris, France
    Hum Immunol 61:1132-7. 2000
    ..The X1 box is the target for RFX complex and an additional factor we identified as Sp1. We propose that the X region in the HLA-G gene promoter might participate to the combination of factors which play a role in HLA-G gene activation...
  54. pmc X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  55. doi request reprint Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversity
    A Sabbagh
    1 Institut de Recherche pour le Développement, UMR 216 Mère et Enfant face aux infections tropicales, Paris, France 2 Faculté de Pharmacie, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Genes Immun 15:95-106. 2014
    ..The 14-bp insertion/deletion polymorphism was further pointed out as the likely target of selection, emphasizing its potential role in the post-transcriptional regulation of HLA-G expression. ..
  56. pmc Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
    D Chiron
    1 INSERM, UMR 892, Centre de Recherches en Cancérologie Nantes Angers, Nantes, France 2 UFR Médecine et Techniques Médicales, Universite de Nantes, Nantes, France 3 CNRS, UMR 6299, Nantes, France
    Blood Cancer J 3:e120. 2013
    ..This study highlights the autocrine role of IGF1 in myeloma cells and reinforces the interest in targeting IGF1R in IGFR1(+) CD45(+/-) patients, such as MMSET(+) patients...
  57. pmc Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
    H Avet-Loiseau
    Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France
    Leukemia 27:711-7. 2013
    ..The additional impact of patient age and use of high-dose therapy was also demonstrated. In conclusion, the combination of iFISH data with ISS staging significantly improves risk assessment in myeloma...
  58. pmc The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
    G Descamps
    INSERM, U892, Univ Nantes, CNRS, UMR 6299, Nantes, F 44000, France
    Br J Cancer 106:1660-7. 2012
    ..As multiple myeloma is an incurable disease that requires new therapeutic approaches, we investigated whether targeting the translation initiation pathway could be a target for myeloma therapy...
  59. doi request reprint A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)
    C Sebban
    Hematology Department, Cancer Centre Léon Bérard, Lyon, France
    Eur J Cancer 48:713-20. 2012
    ....
  60. ncbi request reprint Role of bone marrow transplantation in the disease pathway of myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    J Natl Compr Canc Netw 5:163-9. 2007
    ..Transplant-related mortality associated with this procedure is lower, but more follow-up is needed before definite conclusions can be drawn...
  61. ncbi request reprint Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma
    N C Munshi
    Dana Farber Cancer Institute, Boston, MA Hopital de Nantes, Nantes, France
    J Clin Oncol 27:8602. 2009
    ..The spliced genes identified here are important target for therapy as well as possible immune modulation. No significant financial relationships to disclose...
  62. pmc Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
    C Brosseau
    1 INSERM, UMR 892, Centre de Recherche en Cancérologie Nantes Angers, Nantes, France 2 Université de Nantes, Nantes, France 3 CNRS, UMR 6299, Nantes, France 4 Service d Hématologie, CHU Nantes, Nantes, France
    Cell Death Dis 5:e1389. 2014
    ..These preclinical data provide the rationale to investigate the role of VD3 in vivo in the response to Len. ..
  63. ncbi request reprint Evidence for the presence of the alternatively spliced HLA-G mRNA forms in human mononuclear cells from peripheral blood and umbilical cord blood
    M Kirszenbaum
    CEA DSV DPTE, Laboratoire d Immunoradiobiologie, , Paris, France
    Hum Immunol 43:237-41. 1995
    ..In contrast, we did not revealed any HLA-G transcript in CD34+ fraction of cord blood cells...
  64. ncbi request reprint Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte
    P Brice
    Hopital Saint Louis, Paris, France
    J Clin Oncol 15:1110-7. 1997
    ....
  65. doi request reprint 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
    X Cahu
    Department of Hematology, Centre Hospitalier Universitaire Nantes, France
    Ann Oncol 22:705-11. 2011
    ..In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) during or after therapy is unknown...
  66. doi request reprint Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT
    S Dirou
    1 Centre Hospitalier et Universitaire CHU de Nantes, l institut du thorax, Service de Pneumologie, Nantes, France 2 Faculté de Médecine, Universite de Nantes, Nantes, France
    Bone Marrow Transplant 49:622-7. 2014
    ..26, P=0.27 and P=0.07, respectively). These results correspond favorably with the results obtained with other RIC regimens not incorporating ATG, and suggest that ATG may have a protective pulmonary role after allo-SCT. ..
  67. ncbi request reprint Long-term complications of total body irradiation in adults
    O Thomas
    Department of Radiotherapy, Centre Rene Gauducheau, Saint Herblain, Nantes, France
    Int J Radiat Oncol Biol Phys 49:125-31. 2001
    ..To report long-term pulmonary, thyroid, and ocular complications in patients who had conditioning regimens including total body irradiation (TBI) before bone marrow transplantation (BMT)...
  68. ncbi request reprint Evolving role of stem cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, University Hospital Hotel Dieu, 1 Place Alexis Ricordeau, 44035 Nantes, France
    Clin Lymphoma Myeloma 6:89-95. 2005
    ..Allogeneic stem cell transplantation should be proposed only in the context of a clinical trial...
  69. ncbi request reprint Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
    Frederic Garban
    Hematology Department, University Hospital Hotel Dieu, Place Ricordeau, 44093 Nantes Cedex 01, France
    Blood 107:3474-80. 2006
    ..2 vs 35 months; P = .07). In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose-intensified, melphalan-based ASCT...
  70. ncbi request reprint Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
    Herve Avet-Loiseau
    INSERM Unité 601, Laboratoire d Hematologie, Institut de Biologie, 9 quai Moncousu, 44093 Nantes, France
    Blood 109:3489-95. 2007
    ..In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies...
  71. doi request reprint Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    Herve Avet-Loiseau
    Centre Hospitalier Universitaire, Nantes, France
    J Clin Oncol 28:4630-4. 2010
    ..Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters...
  72. doi request reprint Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
    Herve Avet-Loiseau
    Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France
    Blood 117:2009-11. 2011
    ..28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma...
  73. pmc Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
    P Moreau
    University of Nantes, Nantes, France
    Leukemia 31:115-122. 2017
    ..In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide...
  74. ncbi request reprint Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver
    P Moreau
    CEA, Service de Recherches en Hemato Immunologie, DSV, DRM, Centre Hayem, Hopital Saint Louis, Paris, France
    Hum Immunol 59:751-7. 1998
    ....
  75. ncbi request reprint Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients
    M Baudard
    Service d Hematologie, Centre Hospito Universitaire Hôtel Dieu, Nantes, France
    Bone Marrow Transplant 30:287-95. 2002
    ..Our study highlights the high risk of infectious complications induced by the administration of MMF, an otherwise efficient and well-tolerated treatment for GVHD...
  76. ncbi request reprint t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
    R Garand
    Laboratoire d Hematologie, Centre Hospitalier Universitaire, Nantes, France
    Leukemia 17:2032-5. 2003
    ..In conclusion, our results suggest that a particular morphology can be the signature of chromosomal abnormalities in MM...
  77. ncbi request reprint CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia
    Patrice Chevallier
    Laboratoire d Hematologie, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France
    Br J Haematol 116:142-50. 2002
    ..In conclusion, CD38 expression and secondary 17p deletion are important poor prognostic indicators, especially in Binet stage A CLL...
  78. ncbi request reprint Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
    Philippe Moreau
    Clinical Hematology Department and the Hematology Laboratory, University Hospital, Nantes, France
    Blood 100:1579-83. 2002
    ..These data emphasized the interest in analyzing these two translocations by fluorescence in situ hybridization in prospective therapeutic trials in order to consider these translocations as distinct entities...
  79. ncbi request reprint Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma
    Philippe Moreau
    Department of Clinical Hematology, University Hospital, Nantes, France
    Haematologica 89:547-51. 2004
    ..The aims of this study were to confirm this hypothesis and to test the prognostic value of CD45 expression in newly diagnosed MM patients...
  80. ncbi request reprint High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Arnaud Jaccard
    Department of Hematology, Centre Hospitalier Universitaire, Université et Centre National de la Recherche Scientifique, UMR 6101, Limoges, France
    N Engl J Med 357:1083-93. 2007
    ....
  81. ncbi request reprint Viridans streptococcal bacteraemia in patients with neutropenia
    P Richard
    Laboratoire de Bactériologie A, Hotel Dieu, Nantes, France
    Lancet 345:1607-9. 1995
    ..The oral cavity is a portal of entry for viridans streptococci bacteraemia in neutropenic patients, especially after oral mucosal damage induced by repeated chemotherapy...
  82. doi request reprint FDG-PET in the evaluation of myeloma in 2012
    C Bodet-Milin
    Nuclear Medicine Department, Hotel Dieu, CHU de Nantes, 1, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France CRCNA, INSERM UMR 892, Nantes Cedex 1, France
    Diagn Interv Imaging 94:184-9. 2013
    ..As for the evaluation of lymphomas, the interpretation criteria should be standardised...
  83. doi request reprint Association of HLA-G 3' untranslated region polymorphisms with antibody response against Plasmodium falciparum antigens: preliminary results
    A Sabbagh
    Institut de Recherche pour le Developpement, UMR 216 Mère et Enfant face aux infections tropicales, Paris, France
    Tissue Antigens 82:53-8. 2013
    ..While these results require further investigation, they suggest for the first time a role of HLA-G in the regulation of humoral immune response in malaria...
  84. doi request reprint Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient
    C Bressollette-Bodin
    Virology Laboratory, University Hospital Hotel Dieu and JE2437 Génétique des interactions hôte microorganismes, IFR26, Nantes, France
    Haematologica 93:e39-41. 2008
  85. ncbi request reprint Significant impact of survivin on myeloma cell growth
    M Romagnoli
    1INSERM, UMR 601, 9 quai Moncousu, Nantes, F 44093, France
    Leukemia 21:1070-8. 2007
    ..Finally, survivin knockdown sensitized myeloma cells to conventional anti-myeloma agents. Altogether, these data argue for the interest to evaluate survivin antagonists in MM treatment...
  86. pmc Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study
    Catherine Cordonnier
    Service d Hematologie Clinique, Hopital Henri Mondor, 51 Av Maréchal de Lattre de Tassigny, Creteil, France
    Haematologica 95:1762-8. 2010
    ..Recurrence of prior invasive fungal infection (relapse rate of 30-50%) limits the success of stem cell transplantation. Secondary prophylaxis could reduce disease burden and improve survival...
  87. ncbi request reprint Stem-cell transplantation in multiple myeloma
    Jean Luc Harousseau
    Department of Hematology, Hotel Dieu, Nantes, France
    Best Pract Res Clin Haematol 18:603-18. 2005
    ..The results of allogeneic SCT remain disappointing due to a high transplant mortality. Strategies combining ASCT and reduced-intensity allogeneic SCT are currently being studied...
  88. doi request reprint Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation
    Florent Malard
    Centre Hospitalier et Universitaire CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Biol Blood Marrow Transplant 16:28-34. 2010
    ..014). We conclude that precise monitoring of CsA concentrations and adjustment of CsA dose early after allo-SCT may be effective to prevent onset of severe aGVHD...
  89. doi request reprint Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma
    Aline Clavert
    Service d Hematologie Clinique, Centre Hospitalier et Universitaire CHU de Nantes, Nantes, France
    Leuk Lymphoma 51:1502-8. 2010
    ..We conclude that RIC allo-SCT after auto-SCT is feasible and a potentially efficient therapy for relapsed or transformed aggressive B-cell NHL, warranting further prospective evaluation...
  90. ncbi request reprint HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression
    P Paul
    Service de Recherches en Hemato Immunologie, CEA DRM DSV, Hopital St Louis, Institut Universitaire d Hematologie, 1 avenue Claude Vellefaux, 75475, Cedex 10, Paris, France
    Hum Immunol 61:1177-95. 2000
    ....
  91. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  92. ncbi request reprint CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
    Nelly Robillard
    Laboratory of Hematology and Institut National de la Santé et de la Recherche Médicale INSERM U463, Institute of Biology, Nantes, France
    Blood 102:1070-1. 2003
    ..0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM...
  93. ncbi request reprint Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute mye
    Patrice Chevallier
    Service d Hematologie Clinique, Centre Hospitalier Universitaire, 9 quai Moncousu, BP1005, 44093 Nantes Cedex 01, France
    Leuk Res 29:1003-7. 2005
    ..The MIDAM protocol appears to be highly effective especially in patients with poor risk cytogenetic and/or refractory disease...
  94. ncbi request reprint Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
    Emmanuelle Menoret
    Institut National de la Sante et de la Recherche Medicale, Unite 601, Nantes, F 44000, France
    Blood 108:1346-52. 2006
    ..Taken together, our data clearly encourage clinical trials of anti-TRAILR1 mAb in multiple myeloma, especially for patients whose disease is in relapse, at the time of drug resistance...
  95. ncbi request reprint CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Regis Bataille
    INSERM UMR 601, Institute of Biology, Nantes, France
    Leuk Res 32:379-82. 2008
    ..In conclusion, CD117 (c-kit) is aberrantly expressed on a subset of MGUS and MM with a more indolent presentation and is functionally antinomic to CD221 (IGF-1R). CD117 expression could be related to a specific oncogenic pathway in MM...
  96. doi request reprint Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélom
    Olivier Decaux
    L Institut National de la Santé et de la Recherche Médicale, U892, University of Nantes, University, Hospital, Hematology Laboratory, Nantes, France
    J Clin Oncol 26:4798-805. 2008
    ..We used gene expression profiles of myeloma cells obtained at diagnosis to identify broadly applicable prognostic markers...
  97. pmc Prognostic significance of copy-number alterations in multiple myeloma
    Herve Avet-Loiseau
    L Institut National de la Santé et de la Recherche Médicale U892, Universite de Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, 44093, France
    J Clin Oncol 27:4585-90. 2009
    ..Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown...
  98. ncbi request reprint Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma
    Nicolas Blin
    Haematology Department, University Hospital Hotel Dieu, Place Alexis Ricordeau, Nantes Cedex, France
    Leuk Lymphoma 45:2161-3. 2004
    ..The patient died 1 week after the diagnosis of mucormycosis despite the administration of liposomal amphotericin B. The role of voriconazole and caspofungin in the emergence of mucormycosis is discussed...
  99. ncbi request reprint The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
    Regis Bataille
    INSERM, U601, Nantes, France
    Haematologica 91:1234-40. 2006
    ..Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets...
  100. ncbi request reprint IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop
    Emmanuelle Menoret
    Institut National de la Sante et de la Recherche Medicale, Unité Mixte de Recherche 892, Universite de Nantes, Nantes Atlantique Universites, Nantes, France
    J Immunol 181:6837-42. 2008
    ..These results support that therapy against IGF-1R, which are presently under investigation in multiple myeloma, could be beneficial, not only to suppress IGF-1-mediated myeloma cell growth, but also IL-21-mediated myeloma cell growth...
  101. doi request reprint Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies
    Xavier Cahu
    CHU de Nantes, Service d Hematologie Clinique, Nantes, France
    Biol Blood Marrow Transplant 15:1531-7. 2009
    ..In conclusion, this data suggests that UCBT can be performed in adult patients with hematologic malignancies with an acceptable incidence of IRM provided a sufficient dose of nucleated cells is infused to the patient...